ReviewTrends in microbiology2018
Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe.
Review in Trends in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 214 citations in OpenAlex.
- Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.PLoS neglected tropical diseases · 2023Trial
- Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.Frontiers in immunology · 2019Trial
- Evolutionary Dynamics-AwareACS omega · 2026Article
- Nuclear activities and interactome of the NS5 protein of tick-borne encephalitis virus.Journal of virology · 2026Article
- Article
- Characterization of the virus-host RNA-RNA interactome across important human pathogenic RNA viruses.PLoS pathogens · 2026Article
- LRP8 is a functional receptor for yellow fever virus.Nature microbiology · 2026Article
- Mesenteric Ischemia and Bacterial Translocation Precipitate the Intoxication Phase of Yellow Fever.The Journal of infectious diseases · 2026Article
- Potential Mechanisms Underlying Bleeding During Infection With Hemorrhagic Fever Viruses.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Pulmonary Complications in Fatal Yellow Fever, Brazil, 2017-2019.Emerging infectious diseases · 2026Article
- Nuclear activities and interactome of the NS5 protein of Tick-Borne Encephalitis Virus.bioRxiv : the preprint server for biology · 2026Article
- Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D Vaccine.The American journal of tropical medicine and hygiene · 2026Article
- Viral RNA persistence and long-term consequences following acute infection with Risk Group 4 zoonotic viruses.Frontiers in cellular and infection microbiology · 2026Review
- Yellow Fever, an Arboviral Disease with Public Health Impacts: General Aspects and the Use of the One Health Approach in the Context of This Zoonosis.Infection and drug resistance · 2026Review
- Pharmacovigilance assessment of adverse events following yellow fever vaccination: Disproportionality analysis of VAERS reports, 2015-2025.Human vaccines & immunotherapeutics · 2025Article
- Article
- A single residue in the yellow fever virus envelope protein modulates virion architecture and antigenicity.Nature communications · 2025Article
- Prophylactic and therapeutic neutralizing monoclonal antibody treatment prevents lethal yellow fever infection.JCI insight · 2025Article
- Amino acid changes in two viral proteins drive attenuation of the yellow fever 17D vaccine.Nature microbiology · 2025Article
- Insect-Specific Flaviviruses Have Potential Applications as a Scaffold for Pathogenic Flavivirus Vaccines.Vaccines · 2025Review
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Yellow fever (YF) was one of the most dangerous infectious diseases of the 18th and 19th centuries, resulting in mass casualties in Africa and the Americas. The etiologic agent is yellow fever virus (YFV), and its live-attenuated form, YFV-17D, remains one of the most potent vaccines ever developed. During the first half of the 20th century, vaccination combined with mosquito control eradicated YFV transmission in urban areas. However, the recent 2016-2018 outbreaks in areas with historically low or no YFV activity have raised serious concerns for an estimated 400-500 million unvaccinated people who now live in at-risk areas. Once a forgotten disease, we highlight here that YF still represents a very real threat to human health and economies. As many gaps remain in our understanding of how YFV interacts with the human host and causes disease, there is an urgent need to address these knowledge gaps and propel YFV research forward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.